Clarivate’s ‘drugs to watch’ list signals high prices to come

Clarivate Analytics has released its annual “drug to watch” list, compiled through its Cortellis database of life sciences-focused research and development data.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Campaigners ask US govt to force down prices for common drugs

24 March 2022 Entities backing the Make Meds Affordable campaign have asked US health authorities President Biden to end “patent monopolies” on six common medicines to bring down prices.

Americas

FDA, FTC send message to biologics makers at competition workshop

10 March 2020 US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Clarivate’s ‘drugs to watch’ list signals high prices to come

More on this story

Editor's picks

Editor's picks

More features